Cleveland biotech’s heart failure treatment shows promise; Juventas to launch Phase 3 study next year

Story excerpt provided by The Plain Dealer.  

Written by Brie Zeltner.

A potential new treatment for heart failure developed by Cleveland Clinic spinoff Juventas Therapeutics has shown new promise in a Phase 2 trial, according to data recently released by the Cleveland, Ohio company.

The treatment, a gene therapy called JVS-100 that recruits the body’s own stem cells to repair damaged areas of the heart, was safe and improved cardiac function in patients with advanced heart failure who had heart attacks more than a decade ago.

Click here to read the complete article.

Originally published May 28, 2014.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: